A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
F. Xavier Pi‐Sunyer(Pennington Biomedical Research Center), John Wilding(University of Liverpool), Michel Krempf(Centre de Recherche en Nutrition Humaine Rhône-Alpes), David C.W. Lau(University of Calgary), Arne Astrup(Novo Nordisk Foundation), Ken Fujioka(Scripps Clinic), Frank L. Greenway(Pennington Biomedical Research Center), Christine B. Jensen(Novo Nordisk (Denmark)), Carel W. le Roux(University College Dublin), Rafael Violante Ortíz(Mexican Social Security Institute), Alfredo Halpern(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)
Cited by 2,582
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Inhibition of Food Intake in Obese Subjects by Peptide YY<sub>3–36</sub>
|New England Journal of Medicine|2003|1.6k
Obesity in adults: a clinical practice guideline
|Canadian Medical Association Journal|2020|1.4k
Definition and diagnostic criteria of clinical obesity
|The Lancet Diabetes & Endocrinology|2025|1.3k
2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]
|Canadian Medical Association Journal|2007|1.2k